Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. |  |
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Pizzie Nick | Chief Financial Officer | Feb 13 '25 | Option Exercise | 3.50 | 12,000 | 42,000 | 54,187 | Feb 14 09:20 PM | Pizzie Nick | Chief Financial Officer | Feb 14 '25 | Option Exercise | 3.50 | 3,000 | 10,500 | 45,187 | Feb 14 09:20 PM | Pizzie Nick | Chief Financial Officer | Feb 13 '25 | Sale | 129.86 | 12,000 | 1,558,320 | 42,187 | Feb 14 09:20 PM | Pizzie Nick | Chief Financial Officer | Feb 14 '25 | Sale | 131.07 | 3,000 | 393,210 | 42,187 | Feb 14 09:20 PM | Pizzie Nick | Officer | Feb 14 '25 | Proposed Sale | 131.07 | 3,000 | 393,202 | | Feb 14 04:09 PM | Pizzie Nick | Officer | Feb 13 '25 | Proposed Sale | 129.86 | 12,000 | 1,558,312 | | Feb 13 04:02 PM | Coleman Mark | Director | Jan 03 '25 | Option Exercise | 9.00 | 9,127 | 82,143 | 57,137 | Jan 06 04:06 PM | Coleman Mark | Director | Nov 19 '24 | Option Exercise | 5.94 | 33,410 | 198,455 | 48,010 | Nov 20 04:30 PM | Saad Mark E | Director | Sep 11 '24 | Option Exercise | 3.67 | 11,016 | 40,429 | 21,018 | Sep 11 07:00 PM | Saad Mark E | Director | Sep 11 '24 | Sale | 91.31 | 11,016 | 1,005,871 | 10,002 | Sep 11 07:00 PM | Saad Mark E | Director | Sep 11 '24 | Proposed Sale | 91.31 | 11,016 | 1,005,843 | | Sep 11 04:32 PM | Jacobson Mark L. | Chief Operating Officer | Aug 09 '24 | Option Exercise | 4.04 | 47,739 | 192,866 | 53,522 | Aug 09 07:27 PM | Jacobson Mark L. | Chief Operating Officer | Aug 09 '24 | Sale | 84.26 | 47,739 | 4,022,488 | 5,783 | Aug 09 07:27 PM | Jacobson Mark L. | Officer | Aug 09 '24 | Proposed Sale | 84.26 | 47,739 | 4,022,490 | | Aug 09 05:07 PM | Jacobson Mark L. | Chief Operating Officer | May 29 '24 | Option Exercise | 1.30 | 13,693 | 17,801 | 13,693 | May 29 08:12 PM | Jacobson Mark L. | Chief Operating Officer | May 29 '24 | Sale | 74.31 | 7,910 | 587,813 | 5,783 | May 29 08:12 PM | Coleman Mark | Director | May 28 '24 | Sale | 75.21 | 5,249 | 394,775 | 19,848 | May 29 08:11 PM | Coleman Mark | Director | May 29 '24 | Sale | 75.14 | 5,248 | 394,333 | 14,600 | May 29 08:11 PM | Jacobson Mark L. | Chief Operating Officer | Apr 01 '24 | Option Exercise | 1.30 | 24,662 | 32,061 | 24,662 | Apr 01 06:46 PM | Jacobson Mark L. | Chief Operating Officer | Apr 01 '24 | Sale | 77.24 | 24,662 | 1,904,942 | 0 | Apr 01 06:46 PM | JEFFS ROGER | Director | Mar 14 '24 | Option Exercise | 24.01 | 29,976 | 719,787 | 137,732 | Mar 15 08:05 PM | JEFFS ROGER | Director | Mar 15 '24 | Option Exercise | 29.91 | 2,347 | 70,199 | 123,103 | Mar 15 08:05 PM | JEFFS ROGER | Director | Mar 14 '24 | Sale | 69.70 | 29,976 | 2,089,387 | 120,756 | Mar 15 08:05 PM | JEFFS ROGER | Director | Mar 15 '24 | Sale | 71.61 | 2,347 | 168,062 | 120,756 | Mar 15 08:05 PM |
|